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Guillermo Garcia-ManeroThemyelodysplastic syndromes (MDS) are a com-
plex, heterogeneous group of myeloid malignancies.
The last decade has brought a revolution both in our
ability to classify these disorders and in the number
of nontransplantation therapeutic alternatives avail-
able for patients with MDS. In general, patients with
MDS are classified using the International Prognostic
Scoring System (IPSS) into lower-risk and higher-risk
categories. Approximately two-thirds of MDS patients
are in the lower-risk category at initial presentation.
There is a tendency to observe these patients until
they become transfusion-dependent.
We recently developed a prognostic model that
allows the identification of patients with lower-risk
disease but poor prognosis [1]. This model is based on
a score that considers patient age, cytogenetics, percent-
age of marrow blasts, hemoglobin level, and platelet
count. Depending on the score value, the median
survival of the patients with lower-risk disease can range
from less than 12months to not achieved.Of note, a large
majority of the patients referred to M.D. Anderson
Cancer Center are in the poor-prognosis lower-risk cat-
egory.Validation and prospective use of thismodel could
facilitate allow the development of early interventions,
including allogeneic stem cell transplantation.
Current therapeutic alternatives for patients with
lower-risk disease [2] include supportive care (eg, trans-
fusions, growth factors, antibiotics) and directed thera-
pies, such as lenalidomide in patients with alterations
of chromosome 5 and anemia [3]. The role of hypome-
thylating agents is less well established in these patients;
these agents are commonly used in patients who have
not benefited from growth factor-or lenalidomide-Department of Leukemia, University of Texas M.D.
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investigating the use of lower doses of either decitabine
or 5-azacitidine (including an oral formulation) in these
patients [4-6]. These interventions have not been clearly
shown to modify the natural history of patients with
lower-risk disease, however.
The treatment approach for patients with higher-
risk disease has evolved significantly over the last 5 years.
Previously,most of these patients eitherwere not treated
or were exposed to an acute myelogenous leukemia
(AML)-like induction program. This type of strategy is
associated with higher mortality and short duration of
response. The introduction of hypomethylating agents
has led to significant changes in the treatment of these
patients. Both decitabine and 5-azacitidine have clinical
activity in higher-risk MDS, and a recent randomized
phase III trial found that decitabine therapy improved
survival in patients with higher-risk disease [7,8]. But
despite their activity and excellent toxicity profile,
these agents are associated with relatively low complete
response rates and a prolonged time to response (up
to several months), and, consequently, patients may
be treated chronically with no clear benefit in terms of
transfusion needs. Outcomes are poor in patients who
experience relapse or progress after hypomethylation-
based therapy [9].Theuse of these agents is currently be-
ing incorporated in the treatment of elderly personswith
AML. The use of more intensive therapies in younger
patients is a matter of debate.
Despite these advances, however, the prognosis in
patients with MDS remains poor. This is due in part
to the current lack of molecular targets that can be
used for therapeutic development. Active areas of clin-
ical research include the development of new nontoxic
agents for patients with lower-risk disease, combination
epigenetic therapies for higher-risk disease, and treat-
ments for patients who do not benefit from hypomethy-
lating agents. Various agents aimed at lower-risk MDS
are currently in development, including histone deace-
tylase inhibitors, glutathione S-transferase pi inhibitors,
and p38MAPK inhibitors. As mentioned earlier, several
ongoing studies are investigating very-low-dose decita-
bine and azacitidine therapy; preliminary reports indi-
cate minimal myelosuppressive effects and inductionS9
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[4]. The oral formulation of 5-azacitidine is of interest
as well. Data reported at the 2009 American Society
of Hematology meeting (to be updated at the 2010
meeting) indicate that despite the significantly lower
pharmacokinetic and pharmacodynamic characteristics
of oral 5-azacitidine compared with its parenteral form,
therapy with the oral form is associated with significant
clinical activity and safety in patients with MDS.
Chronic low-dose use also could have a significant im-
pact in patients with lower-risk MDS. Several large-
scale randomized studies in patients with lower-risk
MDS are currently underway, including studies of
lenalidomide in patients non-del5q MDS, thrombomi-
metic agents in patients with thrombocytopenia, and
iron chelation therapy.
Current investigations in higher-risk MDS are
focusing either on attempts to improve current results
with the use of hypomethylating agents upfront or on
the development of new treatment strategies for pa-
tients who no longer benefit from these agents. Combi-
nation epigenetic therapies with histone deacetylase
inhibitors [10] and lenalidomide [11] could potentially
improve outcomes in these patients. Finally, a number
of drugs, including clofarabine and sapacitabine, are
currently under study in the post‒hypomethylating
agent setting. Although these drugs have demonstrated
evidence of clinical activity, most likely they will not
be considered definitive treatments for these patients
[12,13]. Although genetic alterations are rare in
patients with MDS, a small fraction of patients may
harbor alterations of Flt-3, JAK2, and Ras. Specific
inhibitors for these agents, such as MEK inhibitors in
the case of Ras, in development for the treatment of
other leukemias are being investigated in MDS as well.
In summary, a number of investigational and stan-
dard approaches are currently available for patients
with MDS. These approaches, as well as the role of
transplantation, should be carefully discussed with
the patient, family, and physicians involved in the
case and should be based on realistic expectations of
tolerability, natural progression of disease without
therapy, and specific prognostic and molecular charac-
teristics of the patient.ACKNOWLEDGMENTS
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